Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 09/20/2011) - Doctors at NCI will examine people previously diagnosed with MGUS or smoldering myeloma when they enroll in the study, after 6 months, and every 12 months for up to 5 years to identify risk factors or molecular markers that reliably predict which people will progress to full-blown multiple myeloma.
Sequencing Treatment with a PARP Inhibitor and Chemotherapy
(Posted: 09/06/2011) - In this clinical trial, patients will be treated in 21-day cycles, with the first cycle being either intravenous carboplatin on day 1 followed by 7 days of oral olaparib or oral olaparib for 7 days followed by intravenous carboplatin on day 8. In the second cycle, the treatment assignments will be reversed.
Comparing Lung Cancer Targeted Therapies Based on KRAS Mutation Status
(Posted: 08/09/2011) - In this trial, doctors will test the KRAS mutation status of tumors in patients with advanced non-small cell lung cancer whose disease has progressed during or after chemotherapy; they will then randomly assign the patients to either AZD6244 plus erlotinib or either drug alone, depending on KRAS status of their tumors.
Preventing Smoldering Multiple Myeloma from Progressing
(Posted: 07/12/2011) - In this trial, people diagnosed with smoldering myeloma will be treated with an experimental biological agent called IPH2101 that helps immune cells called natural killer cells, or NK cells, attack and destroy myeloma cells.
Adding Targeted Therapy to Treatment for Esophageal Cancer
(Posted: 06/28/2011) - In this phase III clinical trial, people with confirmed HER2-positive locally advanced esophageal cancer will be randomly assigned to receive preoperative radiation therapy and chemotherapy, with or without trastuzumab. Following surgery, patients assigned to the trastuzumab arm of the study will receive maintenance therapy with trastuzumab for 1 year.